AWM
NAMS icon

Atticus Wealth Management’s NewAmsterdam Pharma NAMS Stock Holding History

Atticus Wealth Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$1.12K – 572
2023
Q4 		$1.12K Hold
100
– – ﹤0.01% 512
2023
Q3 		$925 Sell
100
-66
-40% -$715 ﹤0.01% 541
2023
Q2 		$1.97K Hold
166
– – ﹤0.01% 496
2023
Q1 		$2.2K Buy
+166
New +$2.1K ﹤0.01% 470

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Atticus Wealth Management's NAMS Position: Q1 2024 in Review

Atticus Wealth Management sold out of NewAmsterdam Pharma (NAMS) in Q1 2024, closing a stake of 100 shares — an estimated $1.12K sold.

Atticus Wealth Management first reported a position in NAMS in Q1 2023 and held it in 4 quarters. The position peaked at $2.2K in Q1 2023. 76 funds tracked by Wall St. Rank hold NAMS as of Q1 2024.

  • Atticus Wealth Management reported no remaining NewAmsterdam Pharma position as of Q1 2024 after selling out during the quarter.
  • Atticus Wealth Management sold 100 NewAmsterdam Pharma shares in Q1 2024, an estimated $1.12K.
  • Atticus Wealth Management first reported a position in NewAmsterdam Pharma in Q1 2023 and held it in 4 quarters.
  • Atticus Wealth Management's NewAmsterdam Pharma position peaked at $2.2K in Q1 2023.
  • 76 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2024.

Based on Atticus Wealth Management's 13F filing for Q1 2024, filed 17 Apr 2024.